Argenica Therapeutics Ltd (AU:AGN) has released an update.
Argenica Therapeutics Ltd has reached a key milestone in its Phase 2 stroke trial by successfully dosing the first cohort of five acute ischemic stroke patients, with no serious adverse events reported thus far. The trial, which is essential for the safety validation of the neuroprotective drug ARG-007, aims to demonstrate the drug’s efficacy in reducing brain tissue death following a stroke. With three hospitals already actively participating and more to follow, the company anticipates continued progress and will provide updates on recruitment and safety evaluations.
For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.
